Press Releases

China's Infectious Disease Drug Market on Rampage

March 27, 2017

Wellesley, Mass., Mar 27, 2017 – New proprietary research by BCC Research reveals that China is expected to surpass the United States as the world's largest drug-consuming country by 2025, if growth rates from 2016-2021 are any indication. During this period, the Chinese drug market will grow at a 13.9% compound annual growth rate to reach $61.7 billion in the end year.

BCC Research's Infectious Disease Drugs: The Chinese Market reports China's large number of patients has created opportunities for the producers and distributors of infectious disease drugs in both China and other countries. In addition to the 39 common communicable diseases, the country has more than 100 types of communicable and noncommunicable infectious diseases, which consume a huge volume of drugs.

 Research Highlights

  • China is one of the world's largest and fastest-growing drug markets, achieving a 16.8% CAGR in 2015.
  • China's infectious disease drug market will grow by almost $40 billion by 2021.
  • Demand for viral hepatitis, pulmonary tuberculosis and AIDS drug treatment is driving explosive growth in the 39 most common communicable diseases segment.

"The 39 most common communicable diseases have relatively small market values compared to the other more than 100 infectious diseases," says Kevin Fitzgerald, BCC Research editorial director. "Among these diseases, viral hepatitis is the largest sub-segment, accounting for about one-fifth of the total number of new communicable infectious disease cases found in China each year."

Largest and Fastest-Growing Markets

By sales channels, city hospitals will continue to be the largest one for infectious disease drugs in the Chinese market, although its market share will decline from 2015-2021. By sales channels, retail will be the fast-growing segment, with a CAGR of 15.4% from 2016 through 2021.

"By drug product, entecavir will continue as the largest infectious disease drug for the next five years, taking 6.7% of the market by 2021, unless there's a new drug that can replace it in the treatment of viral hepatitis," Fitzgerald notes. "By drug product, voriconazole injection is likely to be the fastest-growing one."

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.

Infectious Disease Drugs: The Chinese Market( PHM178A )
Publish Date:     

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.